|
Media Releases |
Financial Reports |
Presen-tations |
|
08/07/2007
|
|
|
|
| Basel, 07.08.2007 – Lonza announces the availability of Poietics® Human Adipose-Derived Stem Cells (ADSC) for use in adult stem cell research. |
The ADSC system provides research laboratories with ready to use cells and media for research in areas such as tissue repair, wound healing, cell differentiation, osteoporosis, insulin resistance or obesity.
The Poietics® ADSC System contains cryopreserved normal human adipose-derived stem cells and an optimized ADSC growth media kit for cell growth and expansion. Research has indicated that when exposed to specific growth conditions in vitro, these cells can demonstrate various characteristics suggestive of cells from tissues such as fat, bone, cartilage, nerve, muscle and blood vessels to some extent.
“The success of these cells is apparent in their increasing popularity over the past few years as more therapeutic-based companies use adipose tissue as a source of regenerative cells for tissue repair and wound healing in addition to basic research applications associated with adult stem cells”, states Shawn Cavanagh, Head of Lonza Bioscience.
Lonza now manufactures and sells these high quality cells and media through a commercial license with Cytori Therapeutics, Inc, the leader in adipose-derived cell therapy. “We are pleased to be working with Lonza, a leading innovator of life science products, to offer their Poietics® Human Adipose-Derived Stem Cells,” said Eric Daniels, MD, Senior Director, Business Development at Cytori. “This important cell source will provide researchers a platform to study basic cell mechanisms and accelerate regenerative medicine from bench to clinic.”
For more information on this product or to place an order, please visit www.lonzabioscience.com/ADSC. For technical service please call +1 800-638-8174.
About Lonza
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.
Lonza is headquartered in Basel, Switzerland and is listed on the SWX Swiss Exchange. In 2006, Lonza had sales of CHF 2.91 billion. Further information can be found at www.lonza.com.
For further information:
Investor / Media Relations Lonza
Margot Connor
Tel +41 61 316 8566
Fax +41 61 316 9566
margot.connor@lonza.com
Media Relations Lonza German
Dominik Werner
Tel +41 61 316 8798
Fax +41 61 316 9798
dominik.werner@lonza.com
Investor Relations Lonza
Alexandre Pasini
Tel +41 61 316 8835
Fax +41 61 316 9835
alexandre.pasini@lonza.com
|
|
|
